Hansa Biopharma AB (HNSA)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 36.40 |
|---|---|
| 52-week range | 23.52 – 48.22 |
| Return, 1 month / 3 months | +12.5% / −3.8% |
| Return, 1 year / 3 years | +11.2% / +57.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 50 |
| Volatility (1 year) | 63.9% |
| Worst drawdown (1 year) | -39.3% |
| Average daily value traded | 21.92M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, that develops enzyme-based medicines for patients with rare immunological conditions. Its main product is an antibody-cleaving enzyme used to prepare highly sensitised patients for kidney transplantation by removing antibodies that would otherwise cause rejection. The company also studies the same technology in other immune-mediated diseases, working with transplant centres, clinicians and specialist hospital customers.
On this site Hansa Biopharma AB appears as a stock on the Nasdaq Stockholm (Sweden), code HNSA, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hansa Biopharma AB (HNSA) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 36.40 on 27 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 256 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.2% and over the last three months it fell 3.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 6.0% | ||
| From 52-week high | -22.0% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.8% | ||
| 6-month return | 39.9% | ||
| 12-month return, skipping the last month | -1.1% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 63.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.3% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 21.92M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −4.8% |
|---|---|
| 1 month | +12.5% |
| 3 months | −3.8% |
| 6 months | +39.9% |
| 1 year | +11.2% |
| 3 years | +57.4% |
| 5 years | −63.7% |
Signals
| 50-day / 200-day average | 38.36 / 34.34 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.58 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.